Co-Director, Multidisciplinary Breast Cancer Research Program
University of Texas MD Anderson Cancer Center
Member, BCRF Scientific Advisory Board
Staging of cancer is the first step in diagnosis and treatment. TNM staging is the most commonly used staging system in breast cancer and provides information on the extent of the tumor (T), whether it has spread to the lymph nodes (N), and whether the cancer has spread to other parts of the body (metastasized -M). Understanding the stage of the cancer helps doctors to develop a prognosis and design an appropriate treatment plan. Historically, TNM staging has been based solely on anatomic features of the cancer, but breast cancer management requires information about the potential for metastases and response to specific drugs. Drs. Hortobagyi and Berry are conducting an analysis of large patient datasets including cancer registries, the Outcomes Database of the National Comprehensive Cancer Network and three national cooperative clinical trial groups that include robust information on tumor biomarkers and long-term follow up. This study represents the first systematic analysis of existing large databases to determine whether and how some commonly used biomarkers modulate outcome and whether they should serve as the foundation for a new and improved staging classification.
Dr. Gabriel Hortobagyi is an internationally recognized expert in clinical and translational research of breast cancer. He is Professor and the Chair Emeritus of the Department of Breast Medical Oncology at the MD Anderson Cancer Center. He was Hematology/Oncology Training Program Director at MDACC for many years and continues as member of the educational faculty.
He is Past President of the American Society of Clinical Oncology (ASCO) and is one of the world's leading authorities on the management of breast cancer. Dr. Hortobagyi is recipient of numerous awards. He has over 1000 full-length publications in peer-reviewed journals, and over 140 book chapters to his credit. Dr. Hortobagyi served on various task forces and committees of the American Society of Clinical Oncology, served on the Board of Directors, and in 2005 was elected President. He served as President of the International Society of Senology, as a member of the U.S. National Committee for the International Union Against Cancer, the National Cancer Institute’s Breast Cancer Progress Review Group, and the Integration Panel of the Breast Cancer Research Program of the Department of Defense, chaired the Steering Committee of the Breast Health Global Initiative, the Health Advisory Board of the Susan G. Komen Breast Cancer Foundation and the NCI’s Operational Efficiency Working Group. Dr. Hortobagyi is currently the Chair of the Southwest Oncology Group Breast Committee and a member of the Scientific Advisory Board of The Breast Cancer Research Foundation.